IL177193A0 - Anti-cd3 and antigen -specific immunotherapy to treat autoimmunity - Google Patents

Anti-cd3 and antigen -specific immunotherapy to treat autoimmunity

Info

Publication number
IL177193A0
IL177193A0 IL177193A IL17719306A IL177193A0 IL 177193 A0 IL177193 A0 IL 177193A0 IL 177193 A IL177193 A IL 177193A IL 17719306 A IL17719306 A IL 17719306A IL 177193 A0 IL177193 A0 IL 177193A0
Authority
IL
Israel
Prior art keywords
antigen
specific immunotherapy
treat autoimmunity
autoimmunity
treat
Prior art date
Application number
IL177193A
Other languages
English (en)
Original Assignee
Univ Columbia
Jolla Inst Allergy Immunolog
Ucsf Diabetes Ct Of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, Jolla Inst Allergy Immunolog, Ucsf Diabetes Ct Of filed Critical Univ Columbia
Publication of IL177193A0 publication Critical patent/IL177193A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL177193A 2004-02-04 2006-08-01 Anti-cd3 and antigen -specific immunotherapy to treat autoimmunity IL177193A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54195904P 2004-02-04 2004-02-04
PCT/US2005/003712 WO2005076965A2 (fr) 2004-02-04 2005-02-04 Immunotherapie anti-cd3 et specifique d'antigenes pour le traitement de l'auto-immunite

Publications (1)

Publication Number Publication Date
IL177193A0 true IL177193A0 (en) 2006-12-10

Family

ID=34860238

Family Applications (1)

Application Number Title Priority Date Filing Date
IL177193A IL177193A0 (en) 2004-02-04 2006-08-01 Anti-cd3 and antigen -specific immunotherapy to treat autoimmunity

Country Status (7)

Country Link
US (1) US20070190045A1 (fr)
EP (1) EP1725254A4 (fr)
JP (1) JP2007520566A (fr)
AU (1) AU2005213449A1 (fr)
CA (1) CA2554978A1 (fr)
IL (1) IL177193A0 (fr)
WO (1) WO2005076965A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
WO2004035084A2 (fr) * 2002-10-02 2004-04-29 Diamyd Medical Ab Formulation d'antigene
BRPI0511782B8 (pt) * 2004-06-03 2021-05-25 Novimmune Sa anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
EP1848806A4 (fr) * 2005-02-04 2009-09-09 Dow Agrosciences Llc Traitement anti-lymphocytes t et autoantigenique de maladies autoimmunes
JP2009500457A (ja) * 2005-07-11 2009-01-08 マクロジェニクス，インコーポレーテッド 毒性の低下した免疫抑制モノクローナル抗体を使用する自己免疫疾患の治療法
EP2354162A1 (fr) * 2005-09-12 2011-08-10 Novimmune SA Formulations d'anticorps anti-CD3
EP2119450B1 (fr) 2005-11-29 2013-02-13 Actogenix N.V. Induction de tolérance antigénique mucosale pour des auto-antigènes de cellules d'îlot pancréatiques
WO2007084775A2 (fr) * 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions et procedes permettant de moduler l’activation d'un lymphocyte t suppresseur
EP2023955A4 (fr) * 2006-06-06 2009-10-28 Tolerrx Inc Administration d'anticorps anti-cd3 dans le traitement de maladies auto-immunes
EP2037961B1 (fr) 2006-06-14 2015-11-11 MacroGenics, Inc. Procedes de traitement de troubles auto-immuns utilisant des anticorps monoclonaux a toxicite reduite
WO2008079713A2 (fr) * 2006-12-21 2008-07-03 Macrogenics Inc. Procédés pour le traitement du diabète de type lada et d'autres diabètes auto-immuns de l'adulte à l'aide d'anticorps monoclonaux immunosuppresseurs présentant une toxicité réduite
DK2774621T3 (en) 2007-01-25 2018-05-07 Intrexon Actobiotics Nv TREATMENT OF IMMUNE DISEASE BY MUCOSAL ADMINISTRATION OF ANTIGENS
KR20100022022A (ko) * 2007-04-24 2010-02-26 다이아미드 쎄라퓨틱스 아베 자가면역 질환 및 암을 치료하기 위한 의약 및 방법
US20120269826A1 (en) * 2009-10-20 2012-10-25 Mckee Charlotte Anti-cd3 antibody dosing in autoimmune disease
JP2013517329A (ja) * 2010-01-20 2013-05-16 ベイヒル セラピューティクス インコーポレーティッド 自己免疫疾患を処置するための併用治療
US9018006B2 (en) 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
CN106668852B (zh) * 2012-04-13 2020-12-25 艾棣维欣(苏州)生物制药有限公司 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CA2950893C (fr) * 2014-06-04 2023-10-10 Diamyd Medical Ab Nouvelles combinaisons pour therapie a base d'antigene
GB201510056D0 (en) * 2015-06-10 2015-07-22 King S College London Multi-peptide composition
EP3551047A1 (fr) 2016-12-07 2019-10-16 Progenity, Inc. Procédés, dispositifs et systèmes de détection du tractus gastro-intestinal
EP3600416B1 (fr) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libéré à l'aide d'un dispositif ingérable
US11806386B2 (en) 2017-08-07 2023-11-07 St. Vincent's Institute Of Medical Research Type I diabetes therapy
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (fr) 2018-06-20 2019-12-26 Progenity, Inc. Traitement d'une maladie ou d'un état dans un tissu provenant de l'endoderme
AU2019383976A1 (en) 2018-11-19 2021-06-10 Biora Therapeutics, Inc. Methods and devices for treating a disease with biotherapeutics
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
WO2021119482A1 (fr) 2019-12-13 2021-06-17 Progenity, Inc. Dispositif ingérable pour administrer un agent thérapeutique dans le tractus gastro-intestinal
JP2023530109A (ja) 2020-06-11 2023-07-13 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406696B1 (en) * 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
WO1991006319A1 (fr) * 1989-10-27 1991-05-16 Arch Development Corporation Procedes et compositions de promotion de l'immunopotentialisation
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6420140B1 (en) * 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
WO2003028441A1 (fr) * 2001-10-02 2003-04-10 The Board Of Trustees Of The Leland Stanford Junior University Therapie genique pour le prevention de maladies auto-immunes
US20040037826A1 (en) * 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound

Also Published As

Publication number Publication date
JP2007520566A (ja) 2007-07-26
US20070190045A1 (en) 2007-08-16
CA2554978A1 (fr) 2005-08-25
WO2005076965A3 (fr) 2006-07-06
WO2005076965A2 (fr) 2005-08-25
AU2005213449A1 (en) 2005-08-25
EP1725254A2 (fr) 2006-11-29
EP1725254A4 (fr) 2008-02-13

Similar Documents

Publication Publication Date Title
IL177193A0 (en) Anti-cd3 and antigen -specific immunotherapy to treat autoimmunity
HK1099935A1 (en) Anti-cd3 antibodies and methods of use thereof -cd3
IL197831A0 (en) Human antibodies that bind cxcr4 and uses thereof
EP2023955A4 (fr) Administration d'anticorps anti-cd3 dans le traitement de maladies auto-immunes
HK1097859A1 (en) Anti-cd38 human antibodies and uses therefor -cd38
IL178356A0 (en) Dr5 antibodies and uses thereof
IL231169A0 (en) Human monoclonal antibodies to fucosil - 1gm and methods of using antibodies against fucosil - 1gm
IL190332A0 (en) Human antibodies against il13 and therapeutic uses
IL178593A (en) Specific antibodies of fcγriib and methods for their use
EP2097534A4 (fr) Anticorps humains se liant à cd70 et utilisations de ceux-ci
EP1827604A4 (fr) Procedes et compositions pour l' immunotherapie adoptive
IL179476A0 (en) Antibodies against human interleukin-13 and uses therefor
ZA200806723B (en) Combination therapy using anti-EGFR and anti-Her2 antibodies
EP1740300A4 (fr) Composites non-tissés et produits et procédés afférents
IL179891A (en) Antibodies and immune couplings associated with CD44e and their methods and uses
GB0605702D0 (en) Materials and methods for immune cell stimulation
ZA200904657B (en) Human antibodies that bind CD70 and uses thereof
IL180817A0 (en) Specific inhibition of autoimmunity and diseases associated with autoantigens
EP1891407A4 (fr) Dispositifs d'acceleration et procedes d'utilisation correspondants
EP1838288A4 (fr) Materiels et procedes therapeutiques
EP1793857A4 (fr) Therapie combinee utilisant des anticorps anti-ctla4 et anti-4-1bb
EP2097085A4 (fr) Matériaux et procédés thérapeutiques
GB0407382D0 (en) Therapeutic methods and means
ZA200802541B (en) Human antibodies against IL13 and therapeutic uses
GB0407993D0 (en) Therapeutic methods and compositions for use therein